Overview

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
To better understand the safety and tolerability of ALKS 4230 in humans
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
Pembrolizumab